Objectives: To investigate the effect of experimental diabetes and metabolic control on intramembranous bone healing following guided bone regeneration (GBR).
Further studies are warranted to optimise the GBR process in this medically compromised patient population.
Diabetes mellitus is defined as a "group of metabolic diseases characterised by hyperglycaemia resulting from defects in insulin secretion, insulin action, or both" (American Diabetes 2014) , and it is the most common chronic metabolic disease, affecting 8.5% of adults over 18 years of age (World Health Organization 2016) . The number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014 (World Health Organization 2016) , and it has been estimated that between 2010 and 2030, there will be a 69% increase in the number of adults with diabetes in developing countries and a 20% increase in developed countries (Shaw et al. 2010 ). The vast majority of diabetic cases falls in one of the following categories: (a) type 1 diabetes mellitus (T1DM), a condition characterised by absolute deficiency of insulin secretion, resulting from an autoimmune destruction of the insulin producing beta cells of the pancreas; (b) type 2 diabetes mellitus (T2DM), a condition characterised by impaired insulin function, that is resistance to insulin action, combined with an inadequate compensatory insulin secretion response (American Diabetes 2014) .
T1DM is the result of a complex interaction between genes and environmental factors. The genetic component in T1DM aetiology is predominantly associated with high-risk and/or protective HLA haplotypes, residing on the DR and DQ genotypes (Pociot & Lernmark 2016) .
Diabetes mellitus has been associated with the occurrence of a series of complications involving the skeletal system, collectively referred to as "diabetic bone disease" or "diabetic osteopathy" (Bouillon 1991) . The diabetic skeletal phenotype presents the following features: (i) diminished linear bone growth during the pubertal growth spurt in adolescents with diabetes (Salerno et al. 1997; Bizzarri et al. 2014) ; (ii) reduction in bone mineral density and increased risk for occurrence of osteopenia and osteoporosis (Vestergaard 2007) ; (iii) increased fracture risk (Janghorbani et al. 2007 ); (iv) poor osseous healing characteristics and impaired bone regeneration potential (Cozen 1972; Choi et al. 2014; Liuni et al. 2015) .
A meta-analysis by Vestergaard (2007) has shown that, although the relative risk for hip fracture is moderately increased in T2DM patients (1.38, 95% CI: 1.25-1.53), the bone mineral density in the hip and the spine is increased. On the contrary, T1DM is clearly associated with a significantly increased fracture risk (RR = 6.94, 95% CI: 3.25-14.78) and a decreased bone density. As hyperinsulinaemia is associated with increased bone mineral density, it has been hypothesised that the observed clinical dichotomy may be accounted for by the discrepancy in systemic insulin concentration between T1DM and T2DM populations, that is insulinopenia vs. hyperinsulinaemia, respectively (Thrailkill et al. 2005) . Hence, the T1DM skeletal phenotype may represent a more straightforward system to understand the effect of suppressed insulin signalling and hyperglycaemia on the regulation of bone mass and on the osseous healing process (McCabe 2007) .
Suppressed differentiation, proliferation and bone forming capacity of osteoblastic cells during the early healing period have been implicated as plausible pathogenetic mechanisms underlying poor bone formation in T1DM (Jiao et al. 2015; Kalaitzoglou et al. 2016) .
The hyperglycaemic wound healing milieu and the accumulation of advanced glycation end-products (AGEs) have been directly implicated in the impaired ossification potential of diabetic bone (McCarthy et al. 2001; Santana et al. 2003; Kume et al. 2005) . Although it has been documented that abnormal bone repair in experimental diabetes is insulin dependent, since the deficient osseous healing process is reversed by insulin treatment (Goodman & Hori 1984; Hou et al. 1993 ; Suzuki et al. 2003) , it is at present unclear whether this effect is primarily due to the insulin deficiency or to the hyperglycaemia characterising the diabetic status (Thrailkill et al. 2005) .
Guided bone regeneration (GBR) was introduced in 1988 as a therapeutic modality aiming to achieve bone regeneration via the use of barrier membranes (for review see ). The GBR concept is based on the guided tissue regeneration principle, according to which the regeneration of a certain type of tissue is achieved when cells with the capacity to regenerate the particular type of lost tissue are allowed to selectively repopulate the defect during healing (Nyman et al. 1982; Gottlow et al. 1984) . The GBR therapeutic protocol involves the surgical placement of a rigid, cell occlusive membrane facing the bone surface, to physically seal off the skeletal site in need for regeneration (Dahlin et al. 1988 (Dahlin et al. , 1990 . The membrane creates and maintains a secluded space, thus providing an environment that is permissive for the proliferation, differentiation and expression of osteoprogenitor cells. GBR, in association or not with different bone grafts, has been successfully applied for the treatment of critical size defects (CSDs) (Donos et al. 2004 (Donos et al. , 2011a Al-Kattan et al. 2016; Calciolari et al. 2016b,c) , for the regeneration of peri-implant defects (Donos et al. 2008) , for socket preservation (Mardas et al. 2010; Cardaropoli et al. 2012 ) and de novo bone formation (neo-osteogenesis) (Lundgren et al. 1995; Hammerle et al. 1996; Mardas et al. 2003) , in healthy and medically compromised conditions (Donos et al. 2015; Calciolari et al. 2016a ). The calvarial CSD has been widely used in bone regeneration research, as it is easy to reproduce and standardise, and the presence of the dura mater and overlaying skin provide enhanced support and stabilisation to biomaterials (Gomes & Fernandes 2011; Vajgel et al. 2014) . It is considered a very challenging model, as in calvarial CSD the regeneration is supported only by the proliferation and differentiation of osteoprogenitor cells coming from the periphery of the defect ).
The GBR model has been previously applied to study the effect of uncontrolled and systemically insulin-controlled streptozocin-induced diabetes on bone healing in rat calvarial CSDs (Shyng et al. 2001 ) and on de novo bone formation in the mandible ) and calvaria of rats (Fuegl et al. 2011; Lee et al. 2013) .
In the attempt to gain a better understanding of the pathogenic mechanisms of deficient osseous healing in T1DM, the aims of this project were to explore the effect of experimental diabetes and metabolic control on the histological features characterising the different stages of intramembranous bone healing following GBR, and to correlate them to genes differentially expressed at early stages of bone healing.
Material and methods
Ninety-three male Wistar rats, weighing 250 AE 20 g and approximately 8-10 weeks in age, were used in this experimental study. In vivo procedures were conducted in accordance with the Animals Scientific Procedures Act 1986, UK, and under licensure from the Home Office. ARRIVE guidelines for reporting in vivo animal experiments were followed. The rats were observed in the animal facility for at least one week preoperatively and were kept at a constant temperature of 22°C. They were maintained with a light cycle of 12 h (6 am to 6 pm), they had ad libitum access to drinking water and to a standard laboratory diet, and their body weight was weekly monitored.
Experimental diabetes induction, glycaemic control and characterisation
The animals were allocated into three experimental groups, as follows ( Fig. 1 ):
Group H: group with healthy (non-diabetic) controls; Group D: group with uncontrolled diabetes; Group CD: group with controlled diabetes.
At baseline, diabetes was induced in the animals of the D and CD groups, via a single intraperitoneal injection of streptozotocin (STZ) (Sigma-Aldrich, UK) dissolved in citrate buffer (0.01 M; pH 4.3) at a dose of 65 mg/kg of body weight (Bolzan & Bianchi 2002) . The blood glucose levels were monitored enzymatically in tail-nicked samples via the glucose-oxidase method (Accu-Check Advantage; Roche Diagnostics, Indianapolis, USA) at the following time-points: prior to diabetes induction, 7 days after the injection of streptozotocin (to confirm diabetes onset), prior to surgical procedure (21 days after baseline) and at sacrifice. Rats with serum glucose concentrations greater than 270 mg/ dl (15 mmol/l) were considered as diabetic.
Following diabetes confirmation, the animals in the CD group were treated with subcutaneous applications of a sustained-release insulin implant using a trocar/stylet (Linplant TM ©Linshin Canada Inc., Scarborough, Ontario, Canda), which was aseptically placed in the dorsal neck. The sustainedrelease insulin implant contains bovine insulin in an erodible palmitic acid matrix (14% bovine insulin, 86% palmitic acid; weight 26 AE 2 mg/implant) and provides constant insulin release at a rate of 2 IU/day for approximately 30 days (Follak et al. 2004 ). The subcutaneous placement of the systemic insulin delivery device was repeated at 30 and 60 days following the initial delivery.
Experimental Guided Bone Regeneration (GBR) model
Twenty one days following baseline, GBR was performed. General anaesthesia of the animals was accomplished by means of halothane inhalation (3% during induction; 1.5% during maintenance). Following a midline sagittal incision through the skin and the periosteum from the occipital to the frontal region of the calvarium, the cranial vertex was exposed. One standardised, bicortical defect was created at the mid-portion of each parietal bone, by means of a trephine bur General Medical, UK) . The external diameter of the drilled defect was 5 mm, which is considered as a critical size defect (CSD) in rats (Vajgel et al. 2014) . The mid-sagittal suture was not included in the bone defect, in order to preclude its contribution to the bone healing process and to limit the risk of damaging the superior sagittal sinus (Bosch et al. 1995; Donos et al. 2004 ).
In 75 randomly selected animals (25 per group), the defects were treated as follows:
• test site, one defect was covered at both the extracranial and intracranial aspect with an ePTFE non-resorbable membrane (Gore-Tex regenerative membrane, Gore Medical, Arizona, USA);
• control site, the contralateral defect was left untreated.
In the remaining 18 animals (six per group), both calvarial defects were treated with intracranial and extracranial ePTFE non-resorbable barriers according to the GBR principle.
The wound was closed in layers using a resorbable suture (Vicrylâ 5.0, Ethicon, Germany). Buprenorphine hydrochloride (Vetergesic, 0.3 mg/ml, Reckitt Benckiser Healthcare, UK) was administered subcutaneously at a dose of 0.04 mg/kg, and enrofloxacin (Baytrilâ, Bayer, Leverkusen, Germany) was administered subcutaneously at a dose of 2.5 mg/kg and continued per os at a dose of 2.5 mg/kg per day for 7 days.
Of the 75 animals treated with a test and control defect, five animals from each experimental group (H, D and CD) were randomly sacrificed at 3, 7, 15, 30 and 60 days of healing via CO 2 asphyxiation and processed for histology and histomorphometry evaluations.
Of the 18 rats where GBR was applied in both defects, three animals from each experimental group (H, D and CD) were randomly sacrificed at 7 and 15 days of healing via CO 2 asphyxiation and employed for gene expression analysis.
Histological analysis
After euthanasia, block biopsies of 75 animals (25 per group) were prepared and the specimens were fixed in 10% formal saline, followed by decalcification in 5.5% EDTA for at least 2 weeks. Fixed and decalcified samples were dehydrated in a graded series of increasing ethanol concentrations up to 100%, transferred to xylene and embedded into paraffin. Serial sections of 5 lm were obtained perpendicularly to the cranial vertex and in anterior-posterior direction and mounted on poly-L-lysine coated slides. The sections were stained with haematoxylin and eosin. Histological examination of the specimens was performed using a Leitz DM-RBEs microscope (Leica, Heidelberg, Germany) equipped with the Image-Pro Plus v.4.5 Imaging System (Media Cybernetics, Wokingham, UK). Digital photomicrographs were obtained using a CoolsnapPRO-cf digital camera (Media Cybernetics, Marlow, Bucks, UK) connected to the microscope.
Qualitative assessment of the healing outcome was performed and classified as follows (Bosch et al. 1995; Donos et al. 2004 ): • no closure; specimens in which the bone defect remained open, with the exception of minor new bone apposition at the margins of the defect;
• partial closure; specimens in which new bone formation had taken place from the margins of the bone defect, without establishing a complete bone continuity;
• complete closure; specimens in which complete osseous continuity was present between the margins of the defect.
Three central sections of the mid-portion of each defect were used for planimetric analysis. The following linear measurements were performed using the Image-Pro Plus v.4.5 Imaging System:
• residual defect size; the distance between the margins of the newly formed bone in the anterior-posterior dimension excluding any isolated bone spicules present along the central axis;
• initial defect size; the distance delineated by the defect borders in the anterior-posterior dimension.
The percentage of defect bridging was also calculated as the ratio of the difference between the initial and residual defect size to the initial defect size (Bosch et al. 1995) . The mean value of the measurements performed in the three central sections was used for statistical analysis.
All linear measurements were performed by one previously calibrated examiner (MR) at a magnification 920. The reproducibility of the measurements was tested by randomly duplicating 10% of above-mentioned measurements following a minimum two-week interval period. Intra-examiner reproducibility was confirmed via calculation of the intraclass correlation coefficient (ICC = 0.864, 95%CI 0.779-0.876).
Morphometric evaluation was performed using the Image-Pro Plus Imaging System v4.5 (Media Cybernetics, Marlow, Bucks, UK) on one section of the central portion of each specimen, at the marginal and central defect area. Three histomorphometric fields of 100 lm 2 (i.e. one central and two marginal fields) were considered, and morphometric point counting was performed at original magnification of 9400. The results obtained from the two marginal histomorphometric fields were averaged for each section (Bosch et al. 1995) .
In particular, the composition of the tissue within each area was analysed with respect to its content in osteoblasts, fibroblast-like mesenchymal cells, adipocytes, erythrocytes, leucocytes (including polymorphonuclear cells, lymphocytes and plasma cells), monocytes/macrophages, vascular structures, mineralised tissue components and unidentified structures (residual tissue).
Gene expression analysis using Genechip Microarrays
Eighteen animals were used for gene expression analysis, where both calvarial defects were treated according to the GBR principle. On days 7 and 15 of healing, three animals per experimental group were sacrificed and the tissue within each defect was harvested and immediately submerged in 1 ml of RNAlater RNA stabilization reagent (#AM7024, Applied Biosystems/Ambion, Austin TX, USA) and stored at 4°C for a minimum of 24 h and a maximum of 72 h and eventually transferred to À20°C until RNA isolation. The details of Genechip microarray analysis are described elsewhere (Al-Kattan et al. 2016) . Briefly, after RNA isolation, quality and quantity assessment and a Two-Cycle Eukaryotic Target Labeling Assay were performed, to obtain sufficient amounts of labelled cRNA target for analysis with arrays, according to the manufacturer's instructions (http://www.affymetrix.c om/support/technical/manual/expression_ma nual.affx).
The 18 samples were prepared, and the cRNA was hybridised to Affymetrix GeneChip â Rat Genome 230 2.0 Arrays (Rat 230 2.0, Affymetrix, Santa Clara, CA, USA), as previously described (Al-Kattan et al. 2016) . Following 16 h of hybridisation, the microarrays were stained and washed on an Affymetrix GeneChip â Fluidics Station 450. The arrays were scanned on an Affymetrix GeneChip â Scanner 7G, and image files called dat files were created. Based on these image files, the GeneChip â Operating Software (GCOS) computed cell intensity data (.cel files), which were analysed and saved as chp files containing data analysis information for each probe set on the arrays. The Affymetrix MAS 5.0 software was used in order to scale the data to a target intensity of 1,500 and to calculate transcript abundance. The following quality control plots were used to evaluate the Affymetrix data quality:
• boxplots to identify outliers by comparing medians and intensity ranges between samples;
• reproducibility between biological replicates based on density plots comparing the intensity distributions among the arrays;
• histograms of perfect match (PM) vs. mis- • MvA plots with a view to check the reproducibility of biological replicates and to indicate whether large differences in genes expression between groups should be expected in these graphs, M-values, that is log-2 fold change between the intensity value of each probe set in the two samples, are plotted against the Avalues, that is the average intensity of each probe set across all the chips;
• correlation plot, a heatmap of the arrayarray Spearman rank correlation coefficients, has been used to detect outliers.
Statistical analysis
Statistical analysis was performed using the SPSS statistical software (SPSS 14.0, Chicago, IL, USA). The significance of differences among experimental groups in histological bone bridging and in area of regenerated bone per bone length was evaluated using the general linear model (GLM) univariate test, after the assumptions of homogeneity of variance and normality of the residuals distribution were tested. The least significant differences post hoc test for multiple comparisons was used, to evaluate the differences between experimental groups within each treatment type and healing time-point. The level of statistical significance was set at 0.05. Data are reported as mean AE standard error of mean (SE). The composition of the tissue within each area of interest in terms of osteoblasts, fibroblast-like mesenchymal cells, adipocytes, erythrocytes, leucocytes, monocytes/ macrophages, vascular structures, mineralised tissue components and unidentified structures was qualitatively described and presented as 100% stacked bar charts. Differential gene expression between experimental groups was statistically tested using the linear models (LIMMA) in the Bioconductor package v1.9 and R version 2.4.0. LIMMA applies a modified t-test, which uses a Bayesian approach to make the analysis stable even for small sample numbers. Three pairwise comparisons were performed on GC robust multi-array analysis (GCRMA)-normalised data at 7 and 15 days of healing: (i) diabetic vs. healthy; (ii) controlled diabetic vs. diabetic; (iii) controlled diabetic vs. healthy. Summary statistics were compared for each gene and for each paired comparison performed.
The P-values were corrected using the Benjamini-Hochberg test to control the false discovery rate (FDR) following multiple testing. An adjusted P-value cut-off of 0.05 was used to select differentially expressed genes, which means that all genes with an FDR-adjusted value <0.05 were considered as differentially expressed and that the expected proportion of false discoveries was controlled to be less than 5%.
Probe set annotations were derived from the NetAffx website (http://www.affyme trix.com). Supervised hierarchical clustering was performed using all the probe sets with FDR <0.05 in any of the pairwise statistical comparisons. The Manhattan distance metric and average linkage were used for the clustering.
Gene ontology and pathway analyses
Biological interpretation of the GeneChip â expression data was performed via pathway and gene ontology analysis using the Gen-MAPP 2.1 software (Gene Map Annotator and Pathway Profiler), as previously described (Al-Kattan et al. 2016) . For each paired comparison, a data set of significantly altered genes (P < 0.05) presenting at least twofold change was entered into Gen-MAPP. The MAPPFinder and the annotations from the Gene Ontology (GO) Consortium were used to identify underlying processes or mechanisms and global biological trends in gene expression data. More specifically, MAPPFinder calculated the relative amount of differentially expressed genes present within each MAPP/GO term and a statistical z-score of the association of gene expression changes with a particular MAPP/ GO term (Doniger et al. 2003) . A positive zscore indicates that there are more genes linked to a MAPP/GO term than would be expected by random chance. In our analysis, MAPPs with z-score >1.96 (which corresponds to a P-value <0.05) were considered as significantly overrepresented in the differential gene list. In order for a MAPP to be considered for further analysis, it had to include a minimum of five differentially expressed genes.
Results
Healing progressed uneventfully in all animals.
Diabetes induction and characterisation
Blood glucose measurements indicated that diabetes developed by day 7 in groups D and CD, reaching a mean value of 24.4 AE 1.4 mmol/l and 22.3 AE 0.9 mmol/l, respectively.
The threshold level of 15 mmol/l was reached in all the animals that received streptozotocin, whereas diabetes did not develop in the control animals, as expected. Hyperglycaemia was consistent and not transient, as confirmed by the blood glucose measurements during the follow-up period. Delivery of insulin pellets in the CD group led to a reduction in the blood glucose values from 22.3 AE 0.9 mmol/l at day 7, to 9.8 AE 0.6 and 8 AE 0.9 at day 21 and at sacrifice, respectively.
Histological analysis

Three days of healing
In the control sites, at 3 days of healing a blood clot occupied the original defect area, while organisation of a fibrin network throughout the entire defect length was observed in all experimental groups. Numerous erythrocytes were entrapped in the fibrin mesh, while necrotic bone remnants were visible proximally to the original defect borders in some specimens. In addition, few polymorphonuclear cells (PMN) and fibroblastic cells had invaded the fibrin clot ( Fig. 2a-b) .
Seven days of healing
At 7 days of healing, the coagulum remnants had been largely replaced by granulation tissue in both the control and test sites in all experimental groups. In the control sites of all experimental groups, neutrophils and macrophages were sparsely distributed throughout the entire defect length, engulfing damaged tissue. The average defect closure was 19.58 AE 9.10%, 16.02 AE 3.81% and 24.56 AE 3.17% while the regenerated area was 0.89 AE 0.42 mm 2 , 1.27 AE 0.57 mm 2 and 2.73 AE 0.34 mm 2 per mm of defect length in the healthy, uncontrolled diabetic and controlled diabetic animals, respectively (Table 1) .
In the GBR-treated samples, at 7 days of healing the granulation tissue formation differed in comparison with the control sites, in that it characteristically outgrew solely from the marginal bone diploe. The newly formed granulation tissue proximally to the parent bone border presented inflammatory cells and numerous fibroblast-like mesenchymal cells in a provisional, richly vascularised collagenous matrix. However, the central part of the secluded defect space presented only few fibrinous remnants, erythrocytes and scattered inflammatory cells (Fig. 2c-d) . Within the GBR-treated animals, the D group showed a reduced number of PMNs (0.8%), less vascular structures (1.8%) and more abundant haematoma remnants (11.2%) proximally to the defect borders in comparison to group CD. Moreover, the central portion of the GBRtreated sites in the D group presented a less organised fibrin network, with abundant erythrocytes and limited PMN (1%) (Fig. 2c-d) . Morphometric analysis indicated that the provisional granulation tissue matrix in the test specimens of the CD group had a higher proportion of spindle-shape fibroblast-like cells (25.8%) and vascular structures (6%) and similar counts of inflammatory cells (1.2%) compared to the D group ( Fig. 2c-d 
Fifteen days of healing
The control sites in the H and CD groups presented significant woven bone formation extending from the defect margins (28.3% and 43.1%, respectively), while the centre of the defect was filled by dense connective tissue featuring collagens fibers oriented in parallel to the long axis of the defect. The D control specimens presented limited woven bone formation, with reduced osteoblastic cells (4.9%) and vascular structures (10%) in comparison with the healthy control specimens (Fig. 2e-f At 15 days, the GBR-treated healthy (H) and controlled diabetic (CD) animals presented intense appositional bone growth originating from the defect borders and spreading towards the centre of the defect (Fig. 3a) . Only limited inflammatory cells were detected, while osteoblasts, fibroblast-like cells and vascular structures were significantly observed. In five of four GBR-treated uncontrolled diabetic (D) rats, significant new bone formation was noticed. However, the woven bone scaffold appeared as less mature in the D compared to the H group, with fewer spindle-shape fibroblast-like cells (10%) and a higher number of leucocytes (0.6%) adjacent to the defect border (Fig. 2e-f) . Remarkably, in the central part of the defect, mineralised tissue was substantially decreased in the D compared to the H rats (Figs 2e-f and 3b) (Table 1) . A statistically significant reduction in both defect closure and area of new bone was found only in the D compared to the H group (P < 0.05).
Thirty days of healing
Both the defect closure and the area of newly formed bone were significantly higher in the GBR-treated compared to the control animals ( (Fig. 4a ). Complete osseous union had occurred in two H and one CD specimen.
At 30 days, the GBR-treated sites in the D group presented not statistically significant reduced amounts of newly formed bone compared to the H group, with lower remodelling of the primary spongiosa into lamellar bone (Fig. 4b) . Morphometric evaluation indicated that in D specimens, the newly formed mineralised tissue occupied 58.2% of the defect borders and 1.7% of the central part, vs. 74.8% and 26% in the H group, respectively (Fig. 2g-h ). While no inflammatory cells were detected in the H specimens, in the D specimens they occupied 1.3% of the defect borders and 1% of the centre of the defect (Fig. 2g-h Table 1 ). The defect closure in the D group was significantly lower than in the H group (P < 0.05).
Sixty days of healing
In all control groups, limited new bone formation was observed. While in the periphery of the defects, mineralised tissue with a few osteocytes, vascular structures and fibroblastrich connective tissue was observed, the central parts were mainly filled with well-organised fibrous connective tissue, with collagen fibres running in parallel to the long axis of the defect. The average defect closure amounted to 30.21 AE 9.64%, 15.43 AE 4.43% and 11.27 AE 2.94% in the H, D and CD control groups, respectively, whereas the area of new bone was 5.59 AE 1.99 mm 2 , mm of defect length, respectively. Likewise observed at 30 days, also at 60 days the percentage of defect closure and the area of newly formed bone was significantly higher in the GBR-treated compared to the control animals (Table 1 ). In the H group, marked new bone formation occupied the area between the two membranes, with obvious signs of remodelling. Two H specimens presented a complete bridge of regenerated bone (Fig. 5a ). Mineralised tissue occupied 81% of the area adjacent to the defect borders and 58.8% of the central area, thus indicating a significant increase in comparison to day 30. The histology features of the CD group were similar to the H group, and complete defect closure was observed in three specimens (Fig. 5b) . The mineralised tissue significantly increased both in the periphery and central part of the defects (79.4% and 48.6%, respectively; Fig. 2i-j) .
Four of five GBR-treated uncontrolled diabetic (D) rats presented substantial new bone formation and complete osseous union had occurred in one specimen. Proximally to the defect border, the mineralised tissue was comparable to the healthy specimens (71.1%), although the newly mineralised tissue appeared less mature compared to the H group, it had fewer osteocytes (1.6% vs. 3%) and more abundant vascular structures (6.4% vs. 5.2%) and inflammatory cells (0.3% vs. 0%; Figs 2i-j and 5c). In the centre of the defect, increased new bone formation had occurred compared to 30 days, as indicated by the morphometric evaluation of mineralised tissue (26.4% vs. 1.7%; Fig. 2i-j Table 1 ). The differences between the three groups for both parameters were not statistically significant.
RNA quality assessment
All 18 samples featured good RNA quality, with well-resolved ribosomal 18S and 28S RNA peaks and 28S/18S band ratio ≥1.8, although slight degradation was observed in some samples. All RNA samples were therefore considered reliable and utilised for transcriptomic analysis.
Quality control
Following GCRMA normalisation, all box plots examining the distribution of cell intensities overlapped fairly well, thus showing that there was no large variation in the intensity values among the GeneChips and no outlier arrays were identified. M vs. A (MvA) plots showed that, although the spread of M-values was large, the loess curve did not deviate significantly from the M = 0 axis, which indicated good replicate reproducibility.
The intensity distributions of the PM and MM values for each GeneChip were assessed with PMvsMM histograms. All samples had typical PM and MM distributions with the cRNA binding to the MM probes less strongly then to the PM probes in all chips, thus confirming a high signal-to-noise ratio. Finally, the RNA degradation plots were used as a diagnostic tool to evaluate RNA quality among samples. Although the RNA degradation slopes and profiles presented limited viability among the chips, the RNA quality was similar among samples, and as such, all the samples were retained in the data set utilised for analysis. 
Differential gene expression
The number of genes with significantly differential adjusted P-value (FDR <0.05) for each pairwise comparison is shown in Table 2 . The up-and downregulated genes for each paired comparison at 7 and 15 days of healing are presented in Table 3 . The comparison of the diabetic vs. the healthy group at 15 days of healing yielded the largest number of genes with significantly differential expression and was characterised by downregulation of various genes associated with the ossification process, such as bmp4, ltbp4, thra and cd276.
Hierarchical clustering
Supervised hierarchical clustering was performed on a data set consisting of 2,451 probe sets presenting an FDR value less than 0.05 (data not shown). The analysis showed a clear separation between the 7-and 15 day specimens, indicating a characteristic genetic profile related to each stage of intramembranous healing. Overall, the samples of different experimental groups were separated between 7 and 15 days in terms of gene expression. Furthermore, the clustering suggested a clear separation between the D and CD specimens vs. the H specimens at 15 days of healing. Similarly, at 7 days, the D and CD specimens clustered separately vs. the H specimens, even though the separation was less clear.
Gene ontology
Uncontrolled diabetes vs. Healthy
At day 7, 534 probes were upregulated and 230 probes were downregulated in the D vs. the H group at 7 days of healing, which corresponded to 272 upregulated genes and 127 downregulated genes in the uncontrolled diabetic status, which were linked to GO terms. At day 15, 602 probes were upregulated and 1,423 probes were downregulated in the D group, which corresponded to 190 upregulated genes and 966 downregulated genes in the diabetic status, which were linked to GO terms.
A list of selected GO terms is presented in Table 4 . For instance, immune response, inflammatory response, cytokine production, chemokine activity and metabolic processes (e.g. cell proliferation, regulation of cell cycle) were downregulated in the D status at day 7. Conversely, biological processes related to negative regulation of signal transduction, including negative regulation of the Wnt receptor family, were overexpressed in the D vs. the H group.
At 15 days, the regulation of developmental process, regulation of cell morphogenesis, regulation of angiogenesis, humoral immune response and complement activation, as well as cell division, cellular component organisation and biogenesis, actin cytoskeleton organisation and biogenesis were downregulated in the D vs. the H group. Positive signal transduction was also downregulated in the D group, including downregulation of the IkappaB kinase/NF-kappaB cascade and the Wnt receptor signalling pathway. Certain biological processes such as leucocyte activation, lymphocyte activation, T-cell activation, mononuclear cell proliferation and lymphocyte proliferation presented as upregulated in the D compared to the H group at 15 days of healing (Table 4) .
Controlled diabetes vs. Uncontrolled diabetes
At 7 days, 79 probes were upregulated and 76 probes were downregulated in the CD compared to the D group, which corresponded to 51 upregulated genes and 34 genes in the insulin-controlled group, which were linked to GO terms. At 15 days, insulin-mediated glycaemic control was associated with upregulation of 182 probes and downregulation of 187 probes, which corresponded to 84 upregulated genes and 120 downregulated genes in the CD compared to the D group, which were linked to GO terms.
A list of selected GO terms is presented in Table 4 . For instance, at 7 days, insulinmediated glycaemic control was associated with significant upregulation of several GO terms related to biological processes, including cellular organisation and biogenesis, cell surface receptor linked signal transduction, establishment of localisation and transport, protein localisation, protein transport and vesicle-mediated transport. Conversely, posttranslational protein modification and phosphate metabolic process were downregulated in the CD vs. the D group at 7 days of healing.
At 15 days, leucocyte activation, lymphocyte activation and regulation of apoptosis were downregulated in the CD vs. the D group. On the contrary, insulin-mediated glycaemic control was related to upregulation of multicellular organismal development, regulation of developmental process and anatomical structure development (Table 4) .
Controlled diabetes vs. Healthy
At 7 days, 911 probes were upregulated and 384 probes downregulated in the CD compared to the H group, which corresponded to 536 upregulated genes and 200 downregulated genes that linked to GO terms in the controlled diabetic status; 307 probes were upregulated, and 1,120 probes were downregulated in the CD vs. the H group at 15 days of healing, which corresponded to 95 upregulated genes and 770 downregulated genes in the diabetic status, which were linked to GO terms.
At 7 days, numerous biological processes were upregulated in the CD compared to the H group, such as cell adhesion, cellular component organisation and biogenesis, cell growth and cell maturation, cellular localisation, intracellular transport, nuclear transport protein transport, anion transport. In terms of signal transduction, the transmembrane receptor protein serine/threonine kinase signalling pathway, the TGFb receptor signalling pathway and the Wnt receptor signalling pathway were upregulated in the CD group. Furthermore, the GO terms of developmental process, tissue remodelling, skeletal development, ossification and osteoblast differentiation were upregulated in the CD vs. the H group at 7 days of healing. Conversely, the biological processes of immune response, cytokine activity, leucocyte activation, leucocyte migration, angiogenesis, blood vessel morphogenesis, cell activation and response to wounding were underexpressed in the CD group compared to the H group. At 15 days, numerous GO terms related to biological processes were downregulated in the controlled diabetic compared to the healthy group. These included negative regulation of apoptosis, cellular localisation, cellular component organisation and biogenesis, actin filament-based process, microtubule-based process, ribonucleoprotein complex biogenesis and assembly, protein transport and proton transport. Regulation of angiogenesis, regulation of hydrolase activity and protein kinase cascade were also underexpressed in the CD group.
Pathway analysis
Day 7
The pathways differentially expressed between the three groups at 7 days are presented in Table 5 . Seven pathways were significantly enriched in genes differentially expressed in the D vs. H group at 7 days of healing (z score ≥1.96). The D group presented significant downregulation of the cytokines and inflammatory response pathway, the inflammatory response pathway and the IL-1 NetPath 13, whereas the focal adhesion was upregulated in uncontrolled diabetes (Table 5) .
Seven pathways were significantly enriched in genes differentially expressed in the CD vs. D group at 7 days (z score ≥1.96). Particularly, the TGF beta receptor pathway, the IL-5 pathway and the T-cell receptor pathway were upregulated in the insulin-treated group (Table 5) .
Five pathways were significantly enriched in genes differentially expressed in the CD vs. the H group at 7 days of healing (z-score ≥1.96). The insulin-treated group presented significant upregulation of the focal adhesion pathway and downregulation of the IL-1 pathway compared to the healthy group (Table 5) .
Day 15
At 15 days, six pathways were significantly enriched in genes differentially expressed in Table 4 . Selected GO terms significantly overrepresented at 7 and 15 days of healing
In red are the downregulated GO terms in uncontrolled diabetes (D), while in green are the upregulated GO terms in controlled diabetes (CD). the D vs. the H group (z-score ≥1.96). Experimental uncontrolled diabetes was associated with significant downregulation of the TNFa and NF-kB pathway, the electron transport chain pathway, the glycolysis and glyconeogenesis pathway, the proteasome degradation pathway and the complement activation classical pathway (Table 5) .
Four pathways were significantly enriched in genes differentially expressed in the CD vs. the D group at 15 days of healing (z-score ≥1.96), including the T-cell receptor pathway, which was significantly downregulated in the insulin-treated diabetic group (Table 5) .
Finally, eleven pathways were significantly enriched in genes differentially expressed in the CD vs. the H group at 15 days of healing (z-score ≥1.96). The CD group was associated with significant downregulation of several pathways, including the electron transport chain, the glycolysis and glyconeogenesis, the ribosomal proteins, the Krebs TCA cycle and the nucleotide metabolism pathway (Table 5) .
Discussion
This study showed that considerable bone regeneration following GBR can be obtained even in an experimental uncontrolled diabetic status, and it has provided new insights into genes and signalling pathways differently regulated in uncontrolled and insulin-controlled diabetes.
The classic model of streptozotocininduced experimental diabetes was employed, which characteristically presents diminished insulin production and severe hyperglycaemia, thus mimicking the human form of T1DM (Bolzan & Bianchi 2002) . A model of T1DM condition was selected because T1DM is clearly associated with suppressed bone formation and may therefore serve as a more straightforward system to investigate the impact of the hyperglycaemic state and impaired insulin signalling on the bone formation process (McCabe 2007) .
The GBR-treated critical size rat calvarial defect model served as a "gold standard" model for evaluating GBR application. This model presents the advantages of being a standardised, reproducible defect and of providing a physically well-defined in vivo chamber for investigating the intramembranous bone regeneration process following GBR treatment (Bosch et al. 1995; Hammerle et al. 1995; Donos et al. 2004 Donos et al. , 2015 Vajgel et al. 2014) .
It is noteworthy that at 7 days, the defect closure was higher in the control vs. the test sites, whereas at 15 days, it was similar between the test and control sites in all experimental groups. We interpreted these findings of comparable or even inferior new bone formation in the GBR vs. the control sites during the first two weeks of healing as a result of the contribution of osteogenic populations from the dura and the periosteum in the control sites, which were excluded in the membrane-treated sites. It is well established that the dura mater in young animals contains mesesenchymal stem cells, whose differentiation into osteoprogenitor cells promotes osseous repair of calvarial defects (Hobar et al. 1993; Wang & Glimcher 1999) . In addition, preservation of the periosteum has been reported to enhance the regenerative capacity of bone by providing vascular resources and osteoprogenitor cells (EyreBrook 1984) . Hence, although GBR treatment eventually ensures the selective population of the defect by cells originating from the parent calvarial bone, the intracranial and extracranial GBR barrier membranes may also exclude osteogenic tissue resources, which potentially contribute to the osteogenesis process during the initial healing stages. In line with these considerations, the initial increase in defect closure in the healthy control specimens was found to drop at later healing periods, where the lack of a barrier Table 5 . Significantly enriched pathways (z-score >1.96) with genes presenting significantly differential expression (P < 0.05) and minimum twofold change at the 7 and 15 days of healing A criterion of minimum three genes with significantly differential expression was applied for pathway selection. The percentage of differentially expressed genes (% changed), the percentage of genes present in each specific pathway (% present) and the z score are presented. CD, controlled diabetes; D, uncontrolled diabetes; H, healthy controls; GBR, guided bone regeneration. Green is upregulated in D, orange is downregulated in D, blue is upregulated in CD and pink is downregulated in CD.
membrane allowed the migration of nonbone forming soft tissues inside the defect.
Our histological and morphometric evaluations indicated that the uncontrolled diabetic status compromised the initial stages of the intramembranous bone regeneration process following GBR application in critical size rat calvarial defects. This is supported by histological observations of impaired formation of the fibrin meshwork, followed by suppressed inflammatory cell populations and diminished presence of mesenchymal cells in the osseous wound milieu at the end of the first postoperative week (Fig. 2) .
In the GBR-treated sites, at 15 and 30 days of healing, the osteogenesis process was impaired in the presence of uncontrolled diabetes, which was demonstrated by a significant reduction of 38-42% in terms of defect closure and 54-61% in terms of newly formed bone surface compared to the systemically healthy group. However, the effect of diabetes on the bone regeneration potential at the membrane-treated sites was less distinct at 60 days, as opposed to 15 and 30 postoperative days, as the defect closure values in the D group (72 AE 11.7%) were no longer significantly different to the H group (82.2 AE 2.9%; Table 1 ). In other terms, this experiment indicated that, in the presence of uncontrolled diabetes, the sustained application of the GBR principle partially "rescued" the osteogenesis potential during the later stages of the GBR healing process. These findings are in agreement with previous histometric data on GBR in diabetic conditions Lee et al. 2013 ) and confirmed the potential of the GBR application to promote bone regeneration in the presence of uncontrolled experimental diabetes.
It could be suggested that the sustained exclusion of non-osteogenic cell populations from the osseous wound via GBR application maintained an environment permissive for bone formation during the later healing stages of the diabetic osseous wound healing process. Nonetheless, the diabetic status was characterised by diminished influx and/or proliferation of the cells orchestrating the critical early osseous healing events, that is inflammatory, osteoprogenitor and endothelial progenitor cells, in areas distally from the osseous wound margins. Improved glycaemic control achieved via systemic insulin treatment was associated with enhanced granulation tissue formation adjacent to the parent bone margins, as indicated by the increased counts of MSCs and newly formed vascular structures at the end of the first week of healing following GBR application (see Fig. 2 ). In the GBR-treated sites, at 30 and 60 days of healing, systemic insulin-mediated glycaemic control promoted the defect closure values by 32-37% and the newly formed bone surface by 63-89% compared to the uncontrolled diabetic condition, thus conferring a regeneration potential comparable to the healthy animals (Table 1) .
Further to the histological observations of deficient granulation tissue formation and osteogenesis during the critical initial phases following GBR application in the diabetic status, we sought to explore on a molecular level the potentially implicated pathways and to gain insight into the mechanisms via which insulin-mediated glycaemic control improves the early osseous wound healing parameters. Gene expression analysis was performed only at 7 and 15 days of healing because previous studies indicated that these early time-points are critical for skeletogenesis and guided bone regeneration, as they are located in the stage where the initial inflammation is gradually overlapped by a progressive maturation of the granulation tissue into woven bone (Donos et al. 2011b; Ivanovski et al. 2011) .
At 7 days of healing, the uncontrolled diabetic status was characterised by underrepresentation of pathways associated with the inflammatory and immune responses (Table 5 ). More specifically, gene expression profiling indicated impaired expression of genes encoding chemoattractants, such as pro-inflammatory cytokines (Il1a, Il1b, Il6, TNF), chemokines (Ccl20, Cxcl1, Cxcl2, Cxcl10), chemokine receptors (Ccr2, Ccr5, Ccr6) and cell adhesion molecules (Vcam1 and Icam1), all of which are implicated in the migration and activation of inflammatory and mesenchymal cells (Tanaka et al. 1995; Yellowley 2013) . Moreover, a downregulation of the NF-kB signalling cascade was found in the D group at 7 and 15 days of healing. The NF-kB family of transcription factors regulates the transcription of genes encoding key effector molecules for immune and inflammatory responses, such as cytokines, adhesion molecules and chemokines (Hayden et al. 2006; Li & Lin 2008) . Hence, it may be suggested that deficient NF-kB signalling and concomitantly reduced concentrations of chemoattractants in the diabetic osseous healing chamber during early granulation tissue formation may be implicated in aberrant recruitment of inflammatory and mesenchymal cells and therefore account for their diminished presence in the central parts of the osseous wound. It may be further suggested that these observations could relate to the increased risk for infectious complications following GBR treatment in the presence of uncontrolled diabetes.
At 15 days of healing, the inflammatory response was more prominent in the D compared to the H group. More specifically, the T-cell receptor pathway, the leucocyte activation, the lymphocyte activation, the T-cell activation, the mononuclear cell proliferation and the lymphocyte proliferation were overexpressed in the uncontrolled diabetic animals vs. the healthy controls. Therefore, our results indicated that a delayed and prolonged inflammatory response characterised the osseous wound healing events in the diabetic status, which is in accordance with evidence from Lee et al. (2016) , who have shown that experimental T1DM significantly increases the expression of pro-inflammatory cytokines during the regeneration of calvarial CSDs according to the GBR principle. Furthermore, our observations are in accordance with a recent clinical study demonstrating that pro-inflammatory cytokines and chemokines were upregulated in T2DM patients with bone fracture, as well as in osteoblasts subjected to high glucose stimulation (Sun et al. 2016 ).
An anti-inflammatory effect of insulin treatment on the gene profile expressed was evidenced by downregulation of the T-cell receptor pathway, the IL-6 pathway, the leucocyte activation and the lymphocyte activation in the CD compared to the D group at 15 days of healing. These data are in line with previous evidence that insulin downregulates the production of pro-inflammatory cytokines (IL-1, IL6, TNFa) via NF-kB inhibition (Dandona et al. 2001; Sun et al. 2014) , while other studies did not confirm this finding (Pradhan et al. 2009 ).
Furthermore, our gene expression analysis results are in agreement with our histomorphometric observations that the GBR-treated sites in the CD group presented fewer inflammatory cells in the newly formed woven bone proximally to original defect margins at 15 days of healing compared to the uncontrolled diabetic animals.
The diabetes effect on the gene profiles expressed by the cells populating the osseous wound chamber was most prominent at 15 days and characteristically featured downregulation of cell division and of several energy-producing metabolic pathways. These results correlate with our histological observations of reduced numbers of MSCs and osteoblastic cells in the central parts of the GBR-treated defects in the diabetic group at 15 days of healing (Fig. 2e-f) .
Remarkably, a series of genes implicated in the osteogenic process were identified as significantly downregulated in uncontrolled diabetes, including bone morphogenetic protein 4, latent transforming growth factor beta binding protein 4, thyroid hormone receptor alpha and CD276 antigen. Misregulation of these osteogenesis related genes may be directly implicated in the histologically observed impaired osteogenesis potential detected at 15 days of healing following GBR application. Furthermore, Wnt signalling pathway, which plays a major role in osteoblast commitment and differentiation and skeletogenesis (Glass et al. 2005; Monroe et al. 2012) , was misregulated in the diabetic status at 7 and 15 days and, as such, it may be also implicated in the deficient expression of genes involved in the cell division pathway in the diabetic status. Notably, Anagnostou and Shepherd (2008) have also provided evidence indicating that the Wnt/beta-catenin system is a glucose-responsive signalling system and suggested that the Wnt signalling cascade could be misregulated in the hyperglycaemic status. The Wnt-Frizzled signal transduction may therefore constitute a plausible molecular link between uncontrolled diabetes and aberrant cell proliferation during the intramembranous bone healing process following GBR application.
This study presents with some limitations. This animal model allowed to investigate only short-term effects of insulin deficiency, without taking into account potential consequences on bone healing related to the longterm consequences of uncontrolled diabetes (e.g. vasculopathy). Although genomewide transcriptomic analyses provide important data about the molecular mechanisms associated to a biological process, the levels of mRNA are not directly proportional to the expression level of the proteins they code for. The future step will be to combine these results with proteomic data, to have a broader and more precise picture of the mechanisms involved in bone regeneration and of the effect of diabetes at the different stages.
In an attempt to extrapolate our results to a clinical setting, one should consider the higher variability of the treatment outcome in the uncontrolled diabetic status, which is probably related to aberrations during the early phases of the osseous healing process. Consequently, further studies are warranted aiming to optimise the GBR process in this medically compromised patient population. In this context, investigations of the benefits from the use of biomaterials with enhanced osteoinductive or osteoconductive properties for the reconstruction of osseous defects in diabetic patients are necessary.
Carefully designed studies addressing the impact of T2DM and the related higher bone mineral density, insulin resistance and obesity on the pathophysiology of the healing process following GBR application are also warranted.
